TENORVAS Atenolol 50mg Film-Coated Tablet 1's
RXDRUG-DRP-6082-1pc
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Atenolol (Tenorvas) is indicated in hypertension, angina pectoris, myocardial infarction and cardiac arrhythmias. It may also be used in the prophylactic treatment of migraine.
Dosage/Direction for Use
Hypertension: Initially 25-50 mg daily, the dosage gradually may be increased up to 50-100 mg.
Angina pectoris: 100 mg daily in 1-2 divided doses.
Arrhythmias: 50-100 mg daily.
Or as directed by the physician.
Angina pectoris: 100 mg daily in 1-2 divided doses.
Arrhythmias: 50-100 mg daily.
Or as directed by the physician.
Administration
May be taken with or without food.
Contraindications
Atenolol (Tenorvas) is contraindicated in sinus bradycardia, heart failure, second and third degree heart block. Atenolol (Tenorvas) should not be used in patients with any of the following: Known hypersensitivity to the substance; cardiogenic shock, hypotension, metabolic acidosis, severe peripheral circulatory disturbances, sick sinus syndrome, untreated phaeochromocytoma and uncontrolled heart failure.
Special Precautions
Atenolol (Tenorvas) should be administered cautiously in pregnant and lactating mother. Oral dose should be reduced in case of renal failure.
Use In Pregnancy & Lactation
Atenolol (Tenorvas) should be administered cautiously in pregnant and lactating mother.
Adverse Reactions
Reports of sclerosing peritonitis and retroperitoneal fibrosis in patients taking atenolol. Beta blockers are used in the management of cardiac arrhythmias. However, Atenolol 2.5 mg by intravenous injection induced atrial fibrillation in 6 of 12 predisposed patients. A report of reversible cholestatic hepatitis in a patient receiving atenolol and hepatic dysfunction is another. Visual symptoms without headache is associated with atenolol for migraine prophylaxis in a patient who had experienced a similar reaction with nadolol. Precipitous falls in blood pressure in patients with malignant hypertension may cause ischaemic damage to vital organs. Initiating treatment with 1 or 2 oral drugs is considered appropriate but not without risk. Two cases of hypotension following a single oral dose of atenolol 100 mg (27 year old woman) and following 2 oral doses of atenolol 50 mg (51 year old woman) have been reported. The woman had presented with severe hypertension, hyponatraemia, hypokalaemia, and high renin activity. There was a transient elevation of serum creatinine in both patients indicating kidney ischaemia. Renal artery thrombosis believed to be due to the hypotensive effect of atenolol was reported in a 70 year old man with a history of circulatory and cardiac disorders. He had received atenolol 100 mg for treatment of moderate hypertension.
Storage
Store at temperatures not exceeding 30°C. Protect from light.
Action
Pharmacology: Pharmacokinetics: Atenolol (Tenorvas) is incompletely absorbed from the gastrointestinal tract; following oral administration about 50% is absorbed. Peak plasma concentrations are reached in 2 to 4 hours. Atenolol (Tenorvas) has low lipid solubility. It crosses the placenta and is distributed into breast milk where concentrations higher than those in maternal plasma have been achieved. Only small amounts are reported to cross the blood-brain barrier, and plasma-protein binding is minimal. The plasma half-life is about 6 to 7 hours. Atenolol (Tenorvas) undergoes little or no hepatic metabolism and is excreted mainly in the urine.
MedsGo Class
Beta-Blockers
Features
Brand
Tenorvas
Full Details
Dosage Strength
50mg
Drug Ingredients
- Atenolol
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Atenolol
Dosage Form
Film-Coated Tablet
Registration Number
DRP-6082
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply